Cortney Caudill

Cortney Caudill

No más puestos en curso

Fortuna: 552 195 $ al 30/06/2026

Health Technology
Consumer Services

Perfil

Cortney Caudill formerly worked at SAMSUNG BIOLOGICS Co., Ltd., as Director-Business Development Technology, Genentech, Inc., as Principal, VaxGen, Inc., as Principal, Baxalta Schweiz AG, as Head-Drug Product External Manufacturing Network from 2014 to 2016, Spyre Therapeutics, Inc., as Chief Product Officer in 2023, and Halozyme Therapeutics, Inc., as Chief Operating Officer & Senior Vice President from 2025 to 2026.
Ms. Caudill received her Masters Business Admin degree from Fordham University and undergraduate degree from The University of Texas at Austin.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
10/03/2026 7.055 ( 0,01 % ) 552 195 $ 30/06/2026

Antiguos cargos conocidos de Cortney Caudill.

EmpresasCargoFin
HALOZYME THERAPEUTICS, INC. Director de Operaciones 30/06/2026
SPYRE THERAPEUTICS, INC. Director Técnico/Científico/I+D 06/01/2023
Baxalta Schweiz AG
Corporate Officer/Principal 01/02/2016
Corporate Officer/Principal -
Corporate Officer/Principal -
Ver el detalle de la experiencia de Cortney Caudill.

Formación de Cortney Caudill.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

17

Relaciones de 1er grado

8

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas8

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Baxalta Schweiz AG